Abstract
Zika virus (ZIKV) is an arthropod-borne virus (arbovirus) and is primarily transmitted by Aedes species mosquitoes; however, ZIKV can also be sexually transmitted. During the initial epidemic and in places where ZIKV is now considered endemic, it is difficult to disentangle the risks and contributions of sexual versus vector-borne transmission to adverse pregnancy outcomes. To examine the potential impact of sexual transmission of ZIKV on pregnancy outcome, we challenged three rhesus macaques (Macaca mulatta) three times intravaginally with 1 x 107 PFU of a low passage, African lineage ZIKV isolate (ZIKV-DAK) in the first trimester (~30 days gestational age). Samples were collected from all animals initially on days 3 through 10 post challenge, followed by twice, and then once weekly sample collection; ultrasound examinations were performed every 3-4 days then weekly as pregnancies progressed. All three dams had ZIKV RNA detectable in plasma on day 3 post-ZIKV challenge. At approximately 45 days gestation (17-18 days post-challenge), two of the three dams were found with nonviable embryos by ultrasound. Viral RNA was detected in recovered tissues and at the maternal-fetal interface (MFI) in both cases. The remaining viable pregnancy proceeded to near term (~155 days gestational age) and ZIKV RNA was detected at the MFI but not in fetal tissues. These results suggest that sexual transmission of ZIKV may represent an underappreciated risk of pregnancy loss during early gestation.
Introduction
Zika virus (ZIKV) emerged from relative obscurity five years ago to sweep through tropical and subtropical regions of the Western hemisphere. More than a million cases between 2015 and 2018 were reported in Pan American Health Organization (PAHO) regions alone (). While ZIKV primarily causes mild febrile illness or asymptomatic infections in a majority of individuals, infection during pregnancy can result in a range of adverse outcomes including fetal loss and a constellation of birth defects now known as congenital Zika syndrome (CZS) (–). Human infection with ZIKV can occur following mosquito-borne, vertical, and sexual transmission (–). While mosquito-borne transmission from infected Aedes species mosquitoes is thought to be the most common route of infection in endemic areas, the contribution of sexual transmission in epidemics remains poorly understood, in part because during an outbreak, both transmission routes occur simultaneously and can be challenging to disentangle ().
Sexual transmission of ZIKV was first documented in 2008 when a scientist working in Senegal became infected and, upon his return to the United States, infected his wife (). Throughout the ZIKV outbreak in 2015 and 2016, additional sexually-transmitted infections were documented (–). The majority of sexually-transmitted cases in non-endemic areas are likely the result of infection of the primary cases during travel, followed by inadvertent transmission to the secondary cases upon returning home (). As previously mentioned, sexually-transmitted ZIKV infections in endemic areas or areas experiencing active outbreaks are difficult to differentiate from mosquito-transmitted infections because there may be an individual risk of exposure by either route. Epidemiological data suggest that sexual transmission occurs primarily male-to-female through vaginal contact, even weeks after clinical symptom resolution, which suggests that sexual transmission of ZIKV does pose at least a theoretical risk to pregnant women (). Furthermore, the ZIKV viral RNA (vRNA) load in human semen has been reported to range from the hundreds to tens of millions of copies per milliliter, with values as high as 3.98x108 copies/ml reported (–). The testes in particular, were found to be a ZIKV reservoir in animal models (, ). In addition, studies have recently shown that intimate partners of household index cases are more likely to also be positive or show serologic evidence of ZIKV infection relative to other members of the same household ().
Overall, we have limited information regarding the risk of ZIKV sexual transmission to pregnant women and their developing fetuses (). Studies have shown that other sexually transmitted ascending vaginal infections are associated with an increased risk of pre-term labor and other poor outcomes (). Whether an ascending intravaginal ZIKV infection poses a higher risk to pregnancy than mosquito-borne infection is currently unknown. Pregnant women or women trying to become pregnant may be less likely to utilize condoms, a recommended strategy for the prevention of sexual transmission of ZIKV (, ). Furthermore, a woman might not be aware of a pregnancy during early gestation and unfortunately, existing data suggest that the highest risk for developmental anomalies associated with ZIKV infection is during the first trimester, a critical developmental time period (–). Additionally, ZIKV infection during pregnancy has also been associated with an increased risk for spontaneous abortion in both humans and nonhuman primates (, ).
Animal models have played a critical role in improving our understanding of the natural history and pathogenesis of ZIKV. To-date, both murine and nonhuman primate (NHP) models have been utilized to examine aspects of sexual transmission of ZIKV (, , , ). Studies in these models have shown persistent shedding of vRNA from the reproductive tract, infection of the female reproductive tract via a vaginal exposure route, and fetal effects as a result of vaginal exposure or sexual transmission in mice (, –). Although studies in pregnant olive baboons have shown that intravaginal challenge with infected baboon semen during mid-gestation can result in productive maternal infection and vRNA detection in some maternal tissues and placentas, to date, studies in NHP have not shown clear evidence of vertical transmission associated with maternal ZIKV infection by the intravaginal route ().
Because infection during the first trimester is associated with the highest risk for adverse pregnancy outcomes and, since women may be unaware of a pregnancy and may potentially be less likely to utilize barrier methods to prevent sexually-transmitted ZIKV infections during the early first trimester (, ), we designed a proof-of-concept study in which we challenged three gravid rhesus macaques (Macaca mulatta) intravaginally with ZIKV. Our goal was to investigate the potential impact of intravaginal ZIKV challenge during the first trimester on fetal and pregnancy outcomes and to develop a model for sexual transmission during early pregnancy.
Methods
Ethics Statement
All animal procedures conformed to the requirements of the Animal Welfare Act and protocols were approved prior to implementation by the Institutional Animal Care and Use Committee (IACUC) at the University of California, Davis. Activities related to animal care, housing, and diet were performed according to California National Primate Research Center (CNPRC) standard operating procedures (SOPs). SOPs for colony related procedures are reviewed and approved by the UC Davis IACUC.
Study Design
Female rhesus macaques (Macaca mulatta, N=3) were time-mated and identified as pregnant by ultrasound according to established methods (). Prior to study assignment normal embryonic growth and development were confirmed by ultrasound. Females were challenged in the first trimester at approximately 30 days gestational age (trimesters divided by 55-day increments; term 165 ± 10 days) with 1x107 PFU ZIKV-DAK three times intravaginally at approximately two-hour intervals (Table 1 and Figure 1). Pregnancies were monitored by ultrasound every 3-4 days post-challenge and then weekly from day 50 onward throughout the study period. Standardized parameters were assessed including fetal growth (greatest length then biparietal and occipitofrontal diameters, head and abdominal circumferences, humerus and femur lengths) and structural development, amniotic fluid volumes and placental parameters, and compared to normal growth and developmental trajectories for the species (). Dams were weighed at each sedation and blood samples were collected daily from day 3 through day 10 post-challenge, followed by bi-weekly until maternal plasma vRNA loads were undetectable, and then weekly until hysterotomy. Plasma and peripheral blood mononuclear cells (PBMCs) were isolated at all time points, and serum was collected on days 0, 14, and 24 post-challenge (dams 049-102 and 049-103), and on days 0, 14, 27, and 122 post-challenge for dam 049-101. Urine was collected by ultrasound-guided cystocentesis (~1 ml) on days 7, 10, 14, 21, and 24 post-challenge (dams 049-102 and 049-103) and on days 7, 10, 14, 27, and 122 post-challenge for dam 049-101. Hysterotomies were performed for dam 049-102 and 049-103 at the end of the first trimester (post-detection of nonviable embryos by ultrasound) and near term (~155 days gestational age) for dam 049-101.
Table 1
| Dam ID | Weight (kg) | Age (y) | Gestational Age (days) | Scheduled hysterotomy (days) | Virus | Dose (PFU) | Challenge # |
|---|---|---|---|---|---|---|---|
| 049-101 | 5.55 | 6.93 | 29 | 155 | ZIKV-DAK | 1x107 | 3 |
| 049-102 | 7.40 | 11.83 | 32 | 155 | ZIKV-DAK | 1x107 | 3 |
| 049-103 | 8.43 | 12.83 | 31 | 155 | ZIKV-DAK | 1x107 | 3 |
Dam information on day 0 of study.
Figure 1
Virus Challenge Preparation and Infection
ZIKV strain Zika virus/A.africanus-tc/Senegal/1984/DAK AR 41524 (ZIKV-DAK; GenBank: KX601166) was originally isolated from Aedes luteocephalus mosquitoes in Senegal in 1984. One round of amplification on Aedes pseudocutellaris cells, followed by amplification on C6/36 cells and two rounds of amplification on Vero cells, were used to prepare a master stock obtained from BEI Resources (Manassas, VA). Challenge stocks were prepared from this master stock by inoculation onto a confluent monolayer of C6/36 mosquito cells as described previously (). Prior to administration, the ZIKV-DAK stock was diluted to 1x107 PFU in 1Â ml sterile saline and delivered via a 1Â ml tuberculin syringe (). Animals were inoculated three times intravaginally under ketamine sedation at approximately two-hour intervals using a previously described method ().
Blood Processing and Plasma vRNA Loads
Plasma and PBMCs were isolated from blood placed in EDTA vacutainers and processed at 1500 RPM for 15 minutes according to standard protocols. Serum was isolated from whole blood collected into glass vacutainers without additives. Viral RNA was extracted from 300 µl plasma as previously described with a Maxwell 16 MDx instrument (Promega, Madison, WI) and evaluated using qRT-PCR (). RNA concentration was determined by interpolation onto an internal standard curve of seven ten-fold serial dilutions of a synthetic ZIKV RNA segment based on Zika virus/Human/French Polynesia/10087PF/2013 (ZIKV-FP). The limit of quantification of the ZIKV qRT-PCR assay is estimated to be 100 copies vRNA/ml plasma or serum.
Hysterotomy and Tissue Collection
Dams 049-102 and 049-103 were scheduled for hysterotomies in the late first trimester (nonviable embryos detected 3 days prior to hysterotomy). The hysterotomy for dam 049-101 was performed at approximately 155 days gestational age according to the original study design (Figure 1) and following established protocols (). The gestational sac was removed for fetal tissue assessments, with a modified collection protocol for nonviable specimens (see below). For the fetus from dam 049-101 amniotic fluid, fetal blood, and fetal cerebrospinal fluid were collected, then fetal body weights and measures (biparietal and occipitofrontal diameters, abdominal and arm circumferences, hand and foot lengths, humerus and femur lengths, crown-rump length) were assessed. The left cerebral hemisphere and left eye were collected under aseptic conditions and shipped with cold packs to Wisconsin by overnight delivery for additional assessments (see below). Specimens collected for qRT-PCR for vRNA analysis included dura mater; right cerebral hemisphere (frontal, parietal, temporal, occipital lobes); cerebellum (right and left) and midbrain; right optic nerve; right eye (cornea, retina, sclera); spinal cord (cervical, thoracic, lumbar); right and left parotid glands, submandibular, and salivary glands; omentum; thymus; spleen; liver (right, left, quadrate, caudate lobes); pancreas; right and left adrenal glands and kidneys; right and left axillary and inguinal lymph nodes; diaphragm; tracheobronchial and mesenteric lymph nodes; right and left thyroids; trachea; esophagus; pericardium; aorta; right and left atria and ventricles; lung lobes (right and left; all lobes); reproductive tract including right and left gonads; urinary bladder; gastrointestinal tract (stomach, duodenum, jejunum, ileum, colon; meconium), skin, skeletal muscle, and bone marrow (Table 2). The placenta was weighed and assessed including disk measurements (primary and secondary for bidiscoid placentas; primary disk only for monodiscoid), umbilical cord and membrane insertion sites, blood vessel distribution, cut surfaces, and examined for the presence of infarcts. Decidua, membranes, umbilical cord, and multiple sections of the placental disks were collected. All specimens were quick frozen in triplicate over liquid nitrogen for qRT-PCR analysis or collected into RNAlater (cat# R0901, Sigma-Aldrich, St. Louis, MO). Multiple blocks of tissues were collected in histology cassettes fixed in 10% buffered formalin, embedded, sectioned (5-6 µm) and stained with hematoxylin and eosin (H&E) or used for in situ hybridization (ISH).
Table 2
| Dam ID | Organ System/Tissue | Tissue samples tested (N) | Tissue samples qRT-PCR positive (N) | Positive tissue vRNA copies/mg ( ± SD) |
|---|---|---|---|---|
| 049-101 | integumentary | 3 | 0 | 0.0 |
| musculoskeletal | 2 | 0 | 0.0 | |
| nervous | 14 | 0 | 0.0 | |
| endocrine | 7 | 0 | 0.0 | |
| lymphatic | 8 | 0 | 0.0 | |
| cardiovascular | 4 | 0 | 0.0 | |
| respiratory | 10 | 0 | 0.0 | |
| digestive | 12 | 0 | 0.0 | |
| urinary | 3 | 0 | 0.0 | |
| reproductive | 3 | 0 | 0.0 | |
| other | 8 | 0 | 0.0 | |
| primary placental disk | 3 | 2 | 0.66x102a ( ± 0.51x102) | |
| primary placental disk | 3 | 3 | 1.59x103a ( ± 1.20x103) | |
| placenta with decidua | 18 | 3 | 8.13x102a ( ± 3.97x102) | |
| placenta without decidua | 18 | 6 | 6.45x102a ( ± 6.10x102) | |
| decidua | 18 | 3 | 0.0 | |
| 049-102 | nervous (brain) | 1 | 1 | 2.06x103 |
| digestive (liver) | 1 | 1 | 1.23x104 | |
| umbilical cord | 1 | 1 | 8.37x103 | |
| membranes | 1 | 1 | 4.87x103 | |
| primary placental disk | 3 | 3 | 4.96x103a ( ± 4.00x103) | |
| secondary placental disk | 3 | 3 | 3.61x103a ( ± 1.16x103) | |
| decidua | 1 | 0 | 0.0 | |
| 049-103 | nervous (brain) | 1 | 1 | 1.74x105 |
| digestive (liver) | 1 | 1 | 7.42x104 | |
| umbilical cord | 1 | 1 | 7.13x104 | |
| amnion | 1 | 1 | 7.08x102 | |
| chorionic jelly | 1 | 1 | 3.54x103 | |
| membranes (amnion and chorion) | 1 | 1 | 4.74x103 | |
| primary placental disk | 3 | 3 | 1.98x103a ( ± 1.13x103) | |
| secondary placental disk | 3 | 3 | 3.40x103a ( ± 2.18x103) | |
| decidua | 1 | 0 | 0.0 |
Fetal and maternal-fetal interface tissues collected at hysterotomy.
mean vRNA load of multiple positive tissue samples.
For dams 049-102 and 049-103Â a modified collection was performed, consistent with the early developmental stage of the conceptus (Table 2). Decidua, membranes, umbilical cord, and multiple sections of the placental disks were collected as noted above.
Fresh samples collected from the 049-101 fetus (left cerebral hemisphere and left eye) were shipped with cold packs for additional assessments as noted above; the eye was analyzed by the Comparative Ocular Pathology Laboratory of Wisconsin (COPLOW). Placental tissues from all dams and tissues for the fetus from dam 049-101 were assessed as described previously in Koenig et al. ().
Tissue, Urine, and Amniotic Fluid vRNA Loads
Maternal-fetal interface (MFI) and fetal tissue vRNA loads were determined from approximately 20 mg of each specimen. ZIKV RNA was isolated from tissues using the Qiagen AllPrep DNA/RNA Mini Kit (cat# 80284, Qiagen, Germantown MD) using the QIAcube following the manufacturer’s protocol. Viral RNA was isolated from 140 µl maternal urine or amniotic fluid using the QIAmp Viral RNA minikit (cat# 52904, Qiagen, Germantown MD) following the manufacturer’s protocol. Following isolation, cDNA synthesis was performed using the Qiagen Sensiscript RT kit (cat# 205213, Qiagen, Germantown MD) according to the manufacturer’s protocol. Quantification of vRNA load was performed by real-time PCR using the Taqman amplification system and the QuantStudio 12 K Flex Real-Time PCR System (ThermoFisher Scientific, Grand Island, NY) as described previously (). The estimated limit of quantification of the assay is 50-100 ZIKV RNA copies/mg tissue (average = 75 copies/mg).
In Situ Hybridization (ISH)
ISH probes against the ZIKV genome were commercially purchased (cat# 468361, Advanced Cell Diagnostics, Newark, CA). ISH was performed using the RNAscope® Red 2.5 kit (cat# 322350, Advanced Cell Diagnostics, Newark, CA) according to the manufacturer’s protocol. After deparaffinization with xylene, a series of ethanol washes, and peroxidase blocking, sections were heated with the antigen retrieval buffer and then digested by proteinase. Sections were then exposed to the ISH target probe and incubated at 40°C in a hybridization oven for two-hours. After rinsing, ISH signal was amplified using the provided pre-amplifier followed by the amplifier-containing labelled probe binding sites, and developed with a Fast Red chromogenic substrate for 10 minutes at room temperature. Sections were then stained with hematoxylin, air-dried, and mounted.
Plaque Reduction Neutralization Tests (PRNT)
Titers of ZIKV neutralizing antibodies were determined using plaque reduction neutralization tests (PRNT) on Vero cells (ATCC #CCL-81) with a cutoff value of 90% (PRNT90) (). Neutralization curves were generated in GraphPad Prism (San Diego, CA) and the resulting data were analyzed by nonlinear regression to estimate the dilution of serum required to inhibit 90% Vero cell culture infection (, ).
Results
Repeated Intravaginal ZIKV Challenge Results in Infection In Pregnant Macaques
All three dams had detectable ZIKV RNA in plasma by 3 days post intravaginal ZIKV challenge (Figure 2). ZIKV RNA loads peaked on day 5 for dams 049-101 and 049-102, and on day 6 for dam 049-103. Peak vRNA loads ranged from 1.57x104 copies/ml for 049-101 to 1.30x105 copies/ml for 049-103 (Figure 2). The latest detectable plasma vRNA load for animal 049-101 was on day 24 post-challenge (1.56x102 copies/ml). Dam 049-103 had a detectable plasma vRNA load until day 14 (2.46x103 copies/ml) but was negative on day 17 (the next time point samples were collected). Dam 049-102 was consistently positive for ZIKV vRNA until day 14, was negative on day 17, and then positive again on days 21 and 24 post challenge. Dam 049-102 was positive for ZIKV RNA in blood plasma collected at hysterotomy, the last time point sampled for the study. Overall, maternal plasma vRNA loads for dams 049-101, 049-102, and 049-103 were somewhat delayed compared to animals subcutaneously inoculated with French Polynesian or Puerto Rican ZIKV isolates in our previous studies, but were consistent in magnitude with previous observations (, 48, 49). In addition, maternal plasma vRNA loads peaked within a time period similar to subcutaneously inoculated animals infected with the same ZIKV isolate (ZIKV-DAK) () (Figure 2).
Figure 2
Embryonic Demise Following Intravaginal ZIKV Infection During Early Pregnancy
Ultrasound examinations indicated that the embryos of dams 049-102 and 049-103 were nonviable at approximately 17-18 days post-challenge. Hysterotomies were subsequently scheduled and performed and each dam’s final blood and urine samples were collected (Figure 3A). Embryo and placental tissues from dams 049-102 and 049-103 were collected for vRNA analysis, histopathological assessment, and ISH. Dam 049-101’s pregnancy progressed normally and sampling continued until the study endpoint and near-term hysterotomy at approximately 155 days gestational age (Figure 3A). All fetal and placental measurements for 049-101 were recorded and were considered within normal limits for gestational age (Table 3) (
Figure 3

Pregnancy outcomes and maternal-fetal interface (MFI) and fetal tissue vRNA loads. (A) Pregnancy outcomes for three dams intravaginally inoculated 3x with ZIKV at approximately 30 days gestation. Two dams (049-102 and 049-103) were determined by ultrasound to have nonviable embryos at approximately 17-18 days post-ZIKV challenge. Hysterotomies and embryo and MFI tissue collections were performed 3 days after detection. Dam 049-101’s pregnancy continued until scheduled hysterotomy and extensive tissue collection at approximately 155 days gestational age. (B) Average ZIKV vRNA loads for positive embryo and MFI tissues collected at hysterotomy from dams 049-102 (blue) and 049-103 (magenta) following embryonic death at approximately 17-18 days post-ZIKV challenge. The dashed line represents the average of the estimated limit of detection (50-100 copies/mg, average: 75 copies/mg tissue) for the qRT-PCR assay. (C) Average ZIKV vRNA loads for positive MFI tissues collected at hysterotomy from dam 049-101 (orange) at approximately 122 days post-ZIKV infection. Fetal tissues were negative for ZIKV RNA by qRT-PCR. The dashed line represents the average of the estimated limit of detection (50-100 copies/mg, average: 75 copies/mg tissue) for the qRT-PCR assay.
Table 3
| Tissue | Measure (mm) | Weight (g) |
|---|---|---|
| whole body | 180.0 | 405.75 |
| biparietal diameter | 52.3 | – |
| head circumference | 186.0 | – |
| r./l. femur | 52.8/53.0 | – |
| brain | – | 54.42 |
| cerebrum | – | 50.2 |
| cerebellum with midbrain | – | 3.31 |
| cerebellum without midbrain | – | 2.47 |
| r./l. eye | 13.6/13.8 | 1.34/1.35 |
| r./l. thyroid | – | 0.07/0.07 |
| thymus | – | 1.42 |
| spleen | – | 0.58 |
| liver | – | 12.08 |
| r./l. adrenal | – | 0.12/0.17 |
| r./l. kidney | – | 1.00/0.99 |
| lung lobes | – | 8.76 |
| r./l. testis | – | 0.06/0.06 |
| placenta | 145.0 x 85.0 | 159.19 |
049-101 fetal and placental measurements (~155 days gestation, 122 days post challenge).
Measurements were considered to be within normal limits by ultrasound and gross assessment (
MFI, Tissues, and Amniotic Fluid Are ZIKV RNA Positive in Nonviable Embryos
ZIKV RNA was detected in the amniotic fluid from the conceptus of both dams 049-102 and 049-103 at 3.87x103 and 7.38x103 copies/ml respectively at the time of hysterotomy (subsequent to embryonic death). In addition, ZIKV RNA was detected in the brain and liver of both non-viable embryos, as well as in MFI tissues including the primary and secondary placental disks and membranes (amnion and chorion) (Figure 3B). The highest tissue vRNA burden was detected in the brain of the embryo from dam 049-102 (1.74x105 copies/mg). ZIKV RNA was not detected in amniotic fluid collected from the fetus of dam 049-101 at hysterotomy. Although a large number of fetal and MFI tissues were assessed following hysterotomy, the presence of ZIKV RNA was only detected in a subset of sections of MFI tissues from 049-101 (Table 2 and Figure 3C). The decidua from all three dams were negative for ZIKV RNA by qRT-PCR. Similarly, ZIKV RNA was not detected in the urine for any of the dams at any of the time points sampled. Overall, these results highlight the focal nature of ZIKV RNA detection in fetal and MFI tissues following infection during pregnancy. For a number of tissues, multiple samples were collected for vRNA analysis but ZIKV was only detected in a subset of those samples (Table 2).
Changes in Placental Tissues Following Intravaginal ZIKV Infection Are Non-Specific
Histopathological assessments of the placentas of dams 049-102 and 049-103 following embryonic demise showed generalized, non-specific mild necrosis (Table 4 and Supplemental Figures 1–3). In particular, the secondary placental disk from dam 049-102 showed intervillous hemorrhage and parenchymal ischemia (Supplemental Figures 2A, B). In addition, the decidua from dam 049-102 showed some evidence of minimal focal necrosis (Supplemental Figure 2C). Placentas from both dam 049-102 and dam 049-103 had minimal to mild multifocal villous mineralization. The secondary placental disk of dam 049-103 showed acute neutrophilic inflammation, mild focal ischemia, and hemorrhage (Supplemental Figure 3B). Similar to the placentas from the other two dams, the placenta of dam 049-101 showed mild, multifocal villous mineralization, findings which have previously been observed in control placentas. Focal hemorrhage of the primary placental disk basal plate was also noted for dam 049-101 (Supplemental Figure 1A). In addition, decidual tissue from dam 049-101 showed mild, multifocal muscularization of the decidual arteries (Supplemental Figure 1B). Overall, changes in the placental tissues were mild and not associated with any specific pathological processes. Assessment of fetal tissues from dam 049-101 showed normal brain and eye morphology with no identified lesions.
Table 4
| Dam ID | Tissue | Findings |
|---|---|---|
| 049-101 | primary placental disk | focally extensive hemorrhage within the basal plate; mild multifocal villous mineralization |
| decidua | mild multifocal persistent muscularization of decidual arteries | |
| fetal brain | no pathological changes | |
| fetal eye | no pathological changes | |
| fetal lung | mild bilateral diffuse intra-alveolar squamous cells, similar to control | |
| 049-102 | primary placental disk | minimal multifocal villous mineralization |
| secondary placental disk | intervillous hemorrhage and parenchymal ischemia with acute intervillous inflammation involving the lateral margin; not associated with specific pathologic process | |
| decidua | minimal focal necrosis | |
| 049-103 | primary placental disk | mild multifocal mineralization of the anchoring villi |
| secondary placental disk | mild focal parenchymal ischemia with coagulative necrosis and acute neutrophilic inflammation and mild multifocal villous mineralization | |
| decidua | minimal multifocal decidual necrosis with rare neutrophils |
Histopathological assessment of placental tissues from all animals and fetal tissues from 049-101.
ZIKV Genomic RNA Is Detected in MFI Tissues From Demise Cases but Not From the Near-Term Pregnancy
Tissue sections from decidua, primary placental disks, and secondary placental disks (bidiscoid placentas) were assessed by ZIKV ISH using RNAscope (see Methods). ZIKV genomic RNA was detected in both the primary and secondary placental disks from dams 049-102 and 049-103 (Figure 4). No ZIKV RNA was detected by RNAscope in the primary placental disk from dam 049-101, nor any of the decidua sections from any of the pregnancies. The lack of ZIKV RNA in the decidua sections by ISH was consistent with the tissue vRNA assessment by qRT-PCR.
Figure 4

ZIKV genomic RNA was detected by in situ hybridization (ISH) in placental tissues collected from dams 049-102 and 049-103, but not from dam 049-101. For all images, red coloration is indicative of positive staining for ZIKV genomic RNA. Overall, positive staining is focal but visible in multiple areas. Insets show high magnification of the areas denoted by the black arrows in each larger panel. Representative images are shown of (A) primary placental disk from 049-103, (B) secondary placental disk from 049-103, (C) primary placental disk from 049-102, and (D) secondary placental disk from 049-102. Scale bar = 1000 micrometers.
Animals Infected Intravaginally With ZIKV During Pregnancy Develop Neutralizing Antibodies
Serum neutralizing antibody titers (nAbs) against ZIKV were evaluated for dams 049-102 and 049-103 on days 0, 14, and 24 post-challenge by 90% plaque reduction neutralization tests (PRNT90). Serum samples from 0, 14, 27, and 122 days post-challenge collected from dam 049-101 were similarly assessed. Samples collected on day 0 (pre-challenge) from all animals were negative for ZIKV nAbs. Neutralizing Ab titers above 1:10 are indicative of immunity against ZIKV. Serum collected on day 14 post-challenge from all animals neutralized ZIKV-DAK at levels considered protective by PRNT90 (between 1:100 and 1:1000 for each animal). Serum collected on day 24 post-challenge from dams 049-102 and 049-103, and on day 27 post-challenge from dam 049-101 showed an increased neutralization response relative to baseline (day 0) and day 14 for each individual animal (Figure 5). By day 122 post-challenge, the ZIKV nAb response for animal 049-101 was lower than on days 14 or 27, but still demonstrated a strong protective response (PRNT90 titer approximately 1:300) (Figure 5). These results suggest that all animals developed a nAb response against ZIKV following intravaginal ZIKV challenge consistent with findings previously noted for rhesus dams infected subcutaneously (
Figure 5

All three dams developed neutralizing antibodies (nAbs) against ZIKV as detected by PRNT90 following intravaginal ZIKV infection. The x-axis is the log10 reciprocal serum dilution and the y-axis is the percent plaque reduction for ZIKV-DAK. Day 0 for all animals is shown as symbols with 049-101 represented by orange triangles, 049-102 represented by blue circles, and 049-103 represented by magenta squares. Dashed gray horizontal lines indicate the PRNT90 and PRNT50 cut-offs, respectively. Neutralization curves were generated using non-linear regression to estimate the dilution of serum required to inhibit 90% of Vero cell culture infection. Neutralization curves are shown for days 14 (dashed lines) and 24 (dotted lines) for dams 049-102 (blue) and 049-103 (magenta), and for days 14, 27, and 122 (dashed and dotted line) for dam 049-101 (orange).
Discussion
Here we describe a proof-of-concept study that indicates intravaginal challenge with ZIKV during early pregnancy results in productive maternal infection and suggests that infection by this route can result in embryonic demise. ZIKV RNA was detected at the MFI and in embryonic tissues, as well as in the amniotic fluid from the pregnancies of dams 049-102 and 049-103, supporting a role for ZIKV in the adverse pregnancy outcomes for these animals. Although ZIKV was detected by qRT-PCR in the MFI tissues from dam 049-101, no vRNA was detected in fetal tissues directly. Interestingly, although vRNA was detectable in the placenta of dam 049-101 by qRT-PCR, it was not detected by ISH. Given the focal nature of ZIKV RNA detected in the placental tissue samples collected from dam 049-101, it is likely that the samples evaluated by ISH were simply from areas without vRNA present (Table 2). In order to assess transmission in these studies we intentionally avoided any intrauterine sampling to ensure no confounding variables. Because vRNA was not detected in any fetal tissues, our results may suggest that vertical transmission did not occur between dam 049-101 and the developing fetus. Alternatively, the results may suggest immunologic elimination of virus at later gestational ages as previously suggested by a study using direct fetal ZIKV inoculation (
Our results indicating early demise as a result of ZIKV infection are consistent with those described previously in a cross-center, cross-NHP species study (
Some limitations of this study include the use of a relatively high dose of ZIKV to inoculate the dams, the inclusion of multiple challenges over a short timeframe, and the small number of animals included in the study. The dose of inoculum chosen for this study is representative of the high end of the ZIKV vRNA range reportedly detected in human semen, which can be up to 100,000 times higher than that in blood (
We chose to utilize a low passage African ZIKV isolate (ZIKV-DAK) rather than a more contemporary isolate such as the commonly utilized PRVABC59 because, although it is also low passage, recent studies have suggested that this virus may have an attenuated phenotype and is not as pathogenic as ZIKV-DAK in mice (
Many key questions remain with regard to understanding how different ZIKV geographic isolates may differentially impact pregnancy and fetal developmental outcomes. This study suggests that NHP models may be able to differentiate pregnancy outcomes between different isolates. Route of maternal infection may also play a role in pregnancy outcomes, at least in the case of NHP, as intravenous and intra-amniotic ZIKV infections in combination during pregnancy have been associated with a trend toward lower fetal survival rates across multiple studies compared to subcutaneous infections (
Our results suggest that low passage, African lineage virus (ZIKV-DAK) has the potential to result in embryonic demise in rhesus macaques when infection occurs intravaginally and in early pregnancy. To our knowledge, this is the first NHP study to show clear evidence of vertical transmission of ZIKV following intravaginal infection, which has only previously been observed in mice (
Funding
DHHS/PHS/NIH R01 A|1116382-01A1, NIH P51 OD011107 and NIH S10 OD016261.
Statements
Data availability statement
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
Ethics statement
All animal procedures conformed to the requirements of the Animal Welfare Act and protocols were approved prior to implementation by the Institutional Animal Care and Use Committee (IACUC) at the University of California, Davis. Activities related to animal care, housing, and diet were performed according to California National Primate Research Center (CNPRC) standard operating procedures (SOPs). SOPs for colony related procedures are reviewed and approved by the UC Davis IACUC.
Author contributions
CN, AT, CM, and DHO designed the study. AT provided animal oversight and monitoring, ultrasound imaging, and performed all sample collections. AT and CM performed animal infections. AT, MM, MB, XZ, HS, TM, MA, EB analyzed samples. CN, DD, and JR curated data. CN and JR prepared the figures. CN prepared the initial manuscript draft. All authors contributed to the article and approved the submitted version.
Acknowledgments
We thank the research, animal care, and veterinary staff at the California National Primate Research Center for caring for the animals and supporting this study amid the emerging SARS-CoV-2 pandemic. We also thank DHHS/PHS/NIH for providing the supplemental funding for R01 A1116382-01A1 that allowed this work to be completed. These studies were also supported by the California National Primate Research Center base operating grant #OD011107. In vivo imaging was performed with instrumentation funded by an NIH S10 grant #OD016261.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2021.686437/full#supplementary-material
References
1
Zika Cumulative Cases. PAHO. Available at: https://www.paho.org/hq/index.php?option=com_content&view=article&id=12390:zika-cumulative-cases&Itemid=42090&lang=en (Accessed March 22, 2021).
2
MooreCAStaplesJEDobynsWBPessoaAVenturaCVFonsecaEB daet al. Characterizing the Pattern of Anomalies in Congenital Zika Syndrome for Pediatric Clinicians. JAMA Pediatr (2017) 171:288–95. doi: 10.1001/jamapediatrics.2016.3982
3
van der EijkAAvan GenderenPJVerdijkRMReuskenCBMöglingRvan KampenJJAet al. Miscarriage Associated With Zika Virus Infection. N Engl J Med (2016) 375:1002–4. doi: 10.1056/NEJMc1605898
4
AzevedoRSSAraujoMTOliveiraCSFilhoAJMNunesBTDHenriquesDFet al. Zika Virus Epidemic in Brazil. II. Post-Mortem Analyses of Neonates With Microcephaly, Stillbirths, and Miscarriage. J Clin Med Res (2018) 7:496–508. doi: 10.3390/jcm7120496
5
TabataTPetittMPuerta-GuardoHMichlmayrDWangCFang-HooverJet al. Zika Virus Targets Different Primary Human Placental Cells, Suggesting Two Routes for Vertical Transmission. Cell Host Microbe (2016) 20:155–66. doi: 10.1016/j.chom.2016.07.002
6
GregoryCJOduyeboTBraultACBrooksJTChungK-WHillsSet al. Modes of Transmission of Zika Virus. J Infect Dis (2017) 216:S875–83. doi: 10.1093/infdis/jix396
7
CounotteMJKimCRWangJBernsteinKDealCDBroutetNJNet al. Sexual Transmission of Zika Virus and Other Flaviviruses: A Living Systematic Review. PloS Med (2018) 15:e1002611. doi: 10.1371/journal.pmed.1002611
8
de BarrosACWGSantosKGMassadECoelhoFC. Sex-Specific Asymmetrical Attack Rates in Combined Sexual-Vectorial Transmission Epidemics. Microorganisms (2019) 7:112–25. doi: 10.3390/microorganisms7040112
9
FoyBDKobylinskiKCChilson FoyJLBlitvichBJTravassos da RosaAHaddowADet al. Probable Non-Vector-Borne Transmission of Zika Virus, Colorado, USA. Emerg Infect Dis (2011) 17:880–2. doi: 10.3201/eid1705.101939
10
McCarthyM. Zika Virus was Transmitted by Sexual Contact in Texas, Health Officials Report. BMJ (2016) 352:i720. doi: 10.1136/bmj.i720
11
D’OrtenzioEMatheronSYazdanpanahYde LamballerieXHubertBPiorkowskiGet al. Evidence of Sexual Transmission of Zika Virus. N Engl J Med (2016) 374:2195–8. doi: 10.1056/NEJMc1604449
12
DeckardDTChungWMBrooksJTSmithJCWoldaiSHennesseyMet al. Male-to-Male Sexual Transmission of Zika Virus–Texas, January 2016. MMWR Morb Mortal Wkly Rep (2016) 65:372–4. doi: 10.15585/mmwr.mm6514a3
13
DavidsonASlavinskiSKomotoKRakemanJWeissD. Suspected Female-to-Male Sexual Transmission of Zika Virus - New York City, 2016. MMWR Morb Mortal Wkly Rep (2016) 65:716–7. doi: 10.15585/mmwr.mm6528e2
14
YarringtonCDHamerDHKuohungWLee-ParritzA. Congenital Zika Syndrome Arising From Sexual Transmission of Zika Virus, a Case Report. Fertil Res Pract (2019) 5:1. doi: 10.1186/s40738-018-0053-5
15
TurmelJMAbgueguenPHubertBVandammeYMMaquartMLe Guillou-GuillemetteHet al. Late Sexual Transmission of Zika Virus Related to Persistence in the Semen. Lancet (2016) 387:2501. doi: 10.1016/S0140-6736(16)30775-9
16
MussoDRichardVTeissierAStoneMLanteriMCLatoniGet al. Recipient Epidemiology and Donor Evaluation Study (Reds-III) ZIKV Study Group. Detection of Zika Virus RNA in Semen of Asymptomatic Blood Donors. Clin Microbiol Infect (2017) 23:1001.e1–3. doi: 10.1016/j.cmi.2017.07.006
17
MeadPSDuggalNKHookSADeloreyMFischerMOlzenak McGuireDet al. Zika Virus Shedding in Semen of Symptomatic Infected Men. N Engl J Med (2018) 378:1377–85. doi: 10.1056/NEJMoa1711038
18
MansuyJMDutertreMMengelleCFourcadeCMarchouBDelobelPet al. Zika Virus: High Infectious Viral Load in Semen, a New Sexually Transmitted Pathogen? Lancet Infect Dis (2016) 16:405. doi: 10.1016/S1473-3099(16)00138-9
19
McDonaldEMDuggalNKBraultAC. Pathogenesis and Sexual Transmission of Spondweni and Zika Viruses. PloS Negl Trop Dis (2017) 11:e0005990. doi: 10.1371/journal.pntd.0005990
20
DuggalNKRitterJMPestoriusSEZakiSRDavisBSChangG-JJet al. Frequent Zika Virus Sexual Transmission and Prolonged Viral RNA Shedding in an Immunodeficient Mouse Model. Cell Rep (2017) 18:1751–60. doi: 10.1016/j.celrep.2017.01.056
21
RosenbergESDoyleKMunoz-JordanJLKleinLAdamsLLozierMet al. Prevalence and Incidence of Zika Virus Infection Among Household Contacts of Patients With Zika Virus Disease, Puerto Rico, 2016-2017. J Infect Dis (2019) 220:932–9. doi: 10.1093/infdis/jiy689
22
RacicotKCardenasIWünscheVAldoPGullerSMeansREet al. Viral Infection of the Pregnant Cervix Predisposes to Ascending Bacterial Infection. J Immunol (2013) 191:934–41. doi: 10.4049/jimmunol.1300661
23
TeasdaleCAAbramsEJChiassonMAJustmanJBlanchardKJonesHE. Sexual Risk and Intravaginal Practice Behavior Changes During Pregnancy. Arch Sex Behav (2017) 46:539–48. doi: 10.1007/s10508-016-0818-z
24
Salvesen von EssenBKortsmitKWarnerLD’AngeloDVShulmanHBVirellaWHet al. Preventing Sexual Transmission of Zika Virus Infection During Pregnancy, Puerto Rico, USA, 20161. Emerg Infect Dis (2019) 25:2115–9. doi: 10.3201/eid2511.190915
25
HoenBSchaubBFunkALArdillonVBoullardMCabiéAet al. Pregnancy Outcomes After ZIKV Infection in French Territories in the Americas. N Engl J Med (2018) 378:985–94. doi: 10.1056/NEJMoa1709481
26
LinHZTambyahPAYongELBiswasAChanS-Y. A Review of Zika Virus Infections in Pregnancy and Implications for Antenatal Care in Singapore. Singapore Med J (2017) 58:171–8. doi: 10.11622/smedj.2017026
27
Kleber de OliveiraWCortez-EscalanteJDe OliveiraWTGHdo CarmoGMIHenriquesCMPCoelhoGEet al. Increase in Reported Prevalence of Microcephaly in Infants Born to Women Living in Areas With Confirmed Zika Virus Transmission During the First Trimester of Pregnancy - Brazil, 2015. MMWR Morb Mortal Wkly Rep (2016) 65:242–7. doi: 10.15585/mmwr.mm6509e2
28
PomarLMalingerGBenoistGCarlesGVilleYRoussetDet al. Association Between Zika Virus and Fetopathy: A Prospective Cohort Study in French Guiana. Ultrasound Obstet Gynecol (2017) 49:729–36. doi: 10.1002/uog.17404
29
DudleyDMVan RompayKKCoffeyLLArdeshirAKeeslerRIBliss-MoreauEet al. Miscarriage and Stillbirth Following Maternal Zika Virus Infection in Nonhuman Primates. Nat Med (2018) 24:1104–7. doi: 10.1038/s41591-018-0088-5
30
DuggalNKMcDonaldEMRitterJMBraultAC. Sexual Transmission of Zika Virus Enhances In Utero Transmission in a Mouse Model. Sci Rep (2018) 8:4510. doi: 10.1038/s41598-018-22840-6
31
HaddowADPerez-SautuUWileyMRMillerLJKimmelAEPrincipeLMet al. Modeling Mosquito-Borne and Sexual Transmission of Zika Virus in an Enzootic Host, the African Green Monkey. PloS Negl Trop Dis (2020) 14:e0008107. doi: 10.1371/journal.pntd.0008107
32
SchmidtJKMeanKDPuntneyRCAlexanderESSullivanRSimmonsHAet al. Zika Virus in Rhesus Macaque Semen and Reproductive Tract Tissues: A Pilot Study of Acute Infection†. Biol Reprod (2020) 103:1030–42. doi: 10.1093/biolre/ioaa137
33
GurungSNadeauHMaxtedMPeregrineJReuterDNorrisAet al. Maternal Zika Virus (Zikv) Infection Following Vaginal Inoculation With ZIKV-Infected Semen in Timed-Pregnant Olive Baboons. J Virol (2020) 94:1–16. doi: 10.1128/JVI.00058-20
34
PeregrineJGurungSLindgrenMCHusainSZavyMTMyersDAet al. Zika Virus Infection, Reproductive Organ Targeting, and Semen Transmission in the Male Olive Baboon. J Virol (2019) 94:1–16. doi: 10.1128/JVI.01434-19
35
WoollardSMOlwenyiOADuttaDDaveRSMathewsSGorantlaSet al. Preliminary Studies on Immune Response and Viral Pathogenesis of Zika Virus in Rhesus Macaques. Pathogens (2018) 7:70–81. doi: 10.3390/pathogens7030070
36
WinklerCWWoodsTARosenkeRScottDPBestSMPetersonKE. Sexual and Vertical Transmission of Zika Virus in Anti-Interferon Receptor-Treated Rag1-Deficient Mice. Sci Rep (2017) 7:7176. doi: 10.1038/s41598-017-07099-7
37
CarrollTLoMLanteriMDutraJZarbockKSilveiraPet al. Zika Virus Preferentially Replicates in the Female Reproductive Tract After Vaginal Inoculation of Rhesus Macaques. PloS Pathog (2017) 13:e1006537. doi: 10.1371/journal.ppat.1006537
38
TangWWYoungMPMamidiARegla-NavaJAKimKShrestaS. A Mouse Model of Zika Virus Sexual Transmission and Vaginal Viral Replication. Cell Rep (2016) 17:3091–8. doi: 10.1016/j.celrep.2016.11.070
39
YockeyLJVarelaLRakibTKhoury-HanoldWFinkSLStutzBet al. Vaginal Exposure to Zika Virus During Pregnancy Leads to Fetal Brain Infection. Cell (2016) 166:1247–56.e4. doi: 10.1016/j.cell.2016.08.004
40
TAF. Ultrasound Imaging in Rhesus (Macaca mulatta) and Long-Tailed (Macaca fascicularis) Macaques: Reproductive and Research Applications. Lab Primate (2005), 317–52. doi: 10.1016/b978-012080261-6/50020-9
41
JaegerASMurrietaRAGorenLRCrooksCMMoriartyRVWeilerAMet al. Zika Viruses of African and Asian Lineages Cause Fetal Harm in a Mouse Model of Vertical Transmission. PloS Negl Trop Dis (2019) 13:e0007343. doi: 10.1371/journal.pntd.0007343
42
DudleyDMAliotaMTMohrELWeilerAMLehrer-BreyGWeisgrauKLet al. A Rhesus Macaque Model of Asian-lineage Zika Virus Infection. Nat Commun (2016) 7:12204. doi: 10.1038/ncomms12204
43
TarantalAFHartigan-O’ConnorDJPennaEKreutzAMartinezMLNoctorSC. Fetal Rhesus Monkey First Trimester Zika Virus Infection Impacts Cortical Development in the Second and Third Trimesters. Cereb Cortex (2020) 31:2309–21. doi: 10.1093/cercor/bhaa336
44
KoenigMRRazoEMitzeyANewmanCMDudleyDMBreitbachMEet al. Quantitative Definition of Neurobehavior, Vision, Hearing and Brain Volumes in Macaques Congenitally Exposed to Zika Virus. PloS One (2020) 15:e0235877. doi: 10.1371/journal.pone.0235877
45
BreitbachMENewmanCMDudleyDMStewartLMAliotaMTKoenigMRet al. Primary Infection With Dengue or Zika Virus Does Not Affect the Severity of Heterologous Secondary Infection in Macaques. PloS Pathog (2019) 15:e1007766. doi: 10.1371/journal.ppat.1007766
46
LindseyHSCalisherCHMathewsJH. Serum Dilution Neutralization Test for California Group Virus Identification and Serology. J Clin Microbiol (1976) 4:503–10.
47
CrooksCMWeilerAMRybarczykSLBlissMJaegerASMurphyMEet al. African-Lineage Zika Virus Replication Dynamics and Maternal-Fetal Interface Infection in Pregnant Rhesus Macaques. Cold Spring Harbor Lab (2020). doi:Â 10.1101/2020.11.30.405670
48
NguyenSMAntonyKMDudleyDMKohnSSimmonsHAWolfeBet al. Highly Efficient Maternal-Fetal Zika Virus Transmission in Pregnant Rhesus Macaques. PloS Pathog (2017) 13:e1006378. doi: 10.1371/journal.ppat.1006378
49
MohrELBlockLNNewmanCMStewartLMKoenigMSemlerMet al. Ocular and Uteroplacental Pathology in a Macaque Pregnancy With Congenital Zika Virus Infection. PloS One (2018) 13:e0190617. doi: 10.1371/journal.pone.0190617
50
HoneinMADawsonALPetersenEEJonesAMLeeEHYazdyMMet al. Birth Defects Among Fetuses and Infants of US Women With Evidence of Possible Zika Virus Infection During Pregnancy. JAMA (2017) 317:59–68. doi: 10.1001/jama.2016.19006
51
PeñaFPimentelRKhoslaSMehtaSDBritoMO. Zika Virus Epidemic in Pregnant Women, Dominican Republic, 2016-2017. Emerg Infect Dis (2019) 25:247–55. doi: 10.3201/eid2502.181054
52
OspinaMLTongVTGonzalezMValenciaDMercadoMGilboaSMet al. Zika Virus Disease and Pregnancy Outcomes in Colombia. N Engl J Med (2020) 383:537–45. doi: 10.1056/NEJMoa1911023
53
AdesAESoriano-ArandesAAlarconABonfanteFThorneCPeckhamCSet al. Vertical Transmission of Zika Virus and its Outcomes: A Bayesian Synthesis of Prospective Studies. Lancet Infect Dis (2020) 21:537–45. doi: 10.1016/S1473-3099(20)30432-1
54
HendrieTAPetersonPEShortJJTarantalAFRothgarnEHendrieMIet al. Frequency of Prenatal Loss in a Macaque Breeding Colony. Am J Primatol (1996) 40:41–53. doi: 10.1002/(SICI)1098-2345(1996)40:1<41::AID-AJP3>3.0.CO;2-0
55
BrasilPPereiraJP JrMoreiraMERibeiro NogueiraRMDamascenoLWakimotoMet al. Zika Virus Infection in Pregnant Women in Rio De Janeiro. N Engl J Med (2016) 375:2321–34. doi: 10.1056/NEJMoa1602412
56
CohainJSBuxbaumREMankutaD. Spontaneous First Trimester Miscarriage Rates Per Woman Among Parous Women With 1 or More Pregnancies of 24 Weeks or More. BMC Pregnancy Childbirth (2017) 17:437. doi: 10.1186/s12884-017-1620-1
57
Redivo E deFBôtto MenezesCda Costa CastilhoMBrockMda Silva MagnoEGomes Saraiva M dasGet al. Zika Virus Infection in a Cohort of Pregnant Women With Exanthematic Disease in Manaus, Brazilian Amazon. Viruses (2020) 12:1362–77. doi: 10.3390/v12121362
58
OliverAOvertonC. Diagnosis and Management of Miscarriage. Practitioner (2014) 258:25–8.
59
HaddowADNalcaARossiFDMillerLJWileyMRPerez-SautuUet al. High Infection Rates for Adult Macaques After Intravaginal or Intrarectal Inoculation With Zika Virus. Emerg Infect Dis (2017) 23:1274–81. doi: 10.3201/eid2308.170036
60
DuggalNKMcDonaldEMWeger-LucarelliJHawksSARitterJMRomoHet al. Mutations Present in a Low-Passage Zika Virus Isolate Result in Attenuated Pathogenesis in Mice. Virology (2019) 530:19–26. doi: 10.1016/j.virol.2019.02.004
61
DickGWAKitchenSFHaddowAJ. Zika Virus. I. Isolations and Serological Specificity. Trans R Soc Trop Med Hyg (1952) 46:509–20. doi: 10.1016/0035-9203(52)90042-4
62
DickGWA. Zika Virus. II. Pathogenicity and Physical Properties. Trans R Soc Trop Med Hyg (1952) 46:521–34. doi: 10.1016/0035-9203(52)90043-6
63
NuttCAdamsP. Zika in Africa-the Invisible Epidemic? Lancet (2017) 389:1595–6. doi: 10.1016/S0140-6736(17)31051-6
64
MarchiSVivianiSMontomoliETangYBoccutoAVicentiIet al. Zika Virus in West Africa: A Seroepidemiological Study Between 2007 and 2012. Viruses (2020) 12:641–70. doi: 10.3390/v12060641
65
McCraeAWKiryaBG. Yellow Fever and Zika Virus Epizootics and Enzootics in Uganda. Trans R Soc Trop Med Hyg (1982) 76:552–62. doi: 10.1016/0035-9203(82)90161-4
66
DickGW. Epidemiological Notes on Some Viruses Isolated in Uganda; Yellow Fever, Rift Valley Fever, Bwamba Fever, West Nile, Mengo, Semliki Forest, Bunyamwera, Ntaya, Uganda S and Zika Viruses. Trans R Soc Trop Med Hyg (1953) 47:13–48. doi: 10.1016/0035-9203(53)90021-2
67
KiryaBG. A Yellow Fever Epizootic in Zika Forest, Uganda, During 1972: Part 1: Virus Isolation and Sentinel Monkeys. Trans R Soc Trop Med Hyg (1977) 71:254–60. doi: 10.1016/0035-9203(77)90020-7
68
RosenstierneMWSchaltz-BuchholzerFBruzadelliFCóACardosoPJørgensenCSet al. Zika Virus Igg in Infants With Microcephaly, Guinea-Bissau, 2016. Emerg Infect Dis (2018) 24:948–50. doi: 10.3201/eid2405.180153
69
SheridanMAYunusovDBalaramanVAlexenkoAPYabeSVerjovski-AlmeidaSet al. Vulnerability of Primitive Human Placental Trophoblast to Zika Virus. Proc Natl Acad Sci USA (2017) 114:E1587–96. doi: 10.1073/pnas.1616097114
70
SeferovicMSánchez-San MartĂnCTardifSDRutherfordJCastroECCLiTet al. Experimental Zika Virus Infection in the Pregnant Common Marmoset Induces Spontaneous Fetal Loss and Neurodevelopmental Abnormalities. Sci Rep (2018) 8:6851. doi: 10.1038/s41598-018-25205-1
71
DudleyDMAliotaMTMohrELNewmanCMGolosTGFriedrichTCet al. Using Macaques to Address Critical Questions in Zika Virus Research. Annu Rev Virol (2019) 6:481–500. doi: 10.1146/annurev-virology-092818-015732
Summary
Keywords
Zika virus, macaques, pregnancy, intravaginal infection, embryonic loss
Citation
Newman CM, Tarantal AF, Martinez ML, Simmons HA, Morgan TK, Zeng X, Rosinski JR, Bliss MI, Bohm EK, Dudley DM, Aliota MT, Friedrich TC, Miller CJ and O’Connor DH (2021) Early Embryonic Loss Following Intravaginal Zika Virus Challenge in Rhesus Macaques. Front. Immunol. 12:686437. doi: 10.3389/fimmu.2021.686437
Received
26 March 2021
Accepted
04 May 2021
Published
17 May 2021
Volume
12 - 2021
Edited by
Abhay P. S. Rathore, Duke University, United States
Reviewed by
Ashley L. St John, Duke-NUS Medical School, Singapore; Stephen Kent, The University of Melbourne, Australia
Updates

Check for updates
Copyright
© 2021 Newman, Tarantal, Martinez, Simmons, Morgan, Zeng, Rosinski, Bliss, Bohm, Dudley, Aliota, Friedrich, Miller and O’Connor.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: David H. O’Connor, dhoconno@wisc.edu
This article was submitted to Viral Immunology, a section of the journal Frontiers in Immunology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.